Amgen "market perform"

17.12.07 - Rodman & Renshaw

NEW YORK, December 17 (newratings.com) - Analysts at Rodman & Renshaw reiterate their "market perform" rating on Amgen Inc (AMGN).

In a research note published on December 14, the analysts mention that the company has announced favourable results for the HALT Breast Cancer 135 Phase III study. The Phase III data indicates that denosumab raised lumbar spine bone mineral density in patients suffering from breast cancer, the analysts say. Denosumab? sales are likely to start in 2010 and revenues for the breast cancer indication are expected at $250 million by 2015, Rodman & Renshaw adds.